Search | Page 29 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Unrelated Donor Stem Cell Transplantation

    ... sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood ... with matched unrelated donors Other Name: MUD transplant ...

    Clinical Trial last updated 04/27/2016 - 3:18pm.

  2. Cord Blood Transplant

    ... Purpose:  Allogeneic hematopoietic cell transplantation (allo- HCT) is a curative therapy for the treatment of ... donor is the most commonly used source of allogeneic stem cells . However, HLA matched siblings are available for less than one ...

    Clinical Trial last updated 04/27/2016 - 9:59am.

  3. Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

    ... infusion of their donor's bone marrow or blood stem cells . The high-dose chemotherapy drugs and radiation are given to ... Not breastfeeding INCLUSION CRITERIA - HPC-A CELL DONOR At least 18 years of age. Family member (first degree ...

    Clinical Trial last updated 05/09/2016 - 3:01pm.

  4. Nonmyeloablative Haploidentical Transplant Followed by MLN9708

    ... strategies to augment the well documented effect of NK cell alloreactivity seen in HLA -mismatched transplantation. These ... reconstitution following haploidentical peripheral blood stem cell transplantation. Patients will receive a nonmyeloablative ...

    Clinical Trial last updated 04/29/2016 - 1:05pm.

  5. Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

    ... use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to ...

    Clinical Trial last updated 05/03/2016 - 11:45am.

  6. Randomized Allogeneic Azacitidine Study

    ... with AML, CMML, or MDS after an allogeneic (donor) stem cell transplant . The safety of this drug will also be studied. ...

    Clinical Trial last updated 05/03/2016 - 11:08am.

  7. A Phase II Study of 5-Azacitidine and Sargramostim as Maintenance Treatment After Definitive Therapy for Poor-risk AML or MDS

    ... are in remission after definitive treatment with either stem cell transplant or cytarabine-based consolidation chemotherapy . ...

    Clinical Trial last updated 05/03/2016 - 10:38am.

  8. Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

    ... of two novel conditioning therapies for hematopoietic stem cell transplant (HSCT). The primary focus of both the investigators' ...

    Clinical Trial last updated 05/03/2016 - 10:36am.

  9. "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution

    ... sibling donor or are too old for hematopoietic stem cell transplant . Approximately two thirds of patients successfully respond ...

    Research Review last updated 05/02/2016 - 9:13am.

  10. GVAX vs. Placebo for MDS/AML After Allo HSCT

    ... your MDS or AML from relapsing after your allogeneic stem cell transplantation. "Investigational" means that the vaccine is still being ...

    Clinical Trial last updated 04/28/2016 - 12:01pm.